The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

BNZ looks to economic uptick supporting its full year 2026 outturn
Finance

BNZ looks to economic uptick supporting its full year 2026 outturn

BNZ is the latest bank to cautiously spruik GDP growth in 2026.

BNZ profit dips as economic return proves sluggish
Finance

BNZ profit dips as economic return proves sluggish

Net-interest margin tiptoes higher but total operating income slips. 

Andy Macdonald 06 Nov 2025
NZ's financial stability risks higher than in recent years
Finance

NZ's financial stability risks higher than in recent years

The RBNZ says global uncertainty and underperformance are key factors.

Staff reporters 05 Nov 2025
Trade Me parent company appoints Owen Wilson as director
Finance

Trade Me parent company appoints Owen Wilson as director

Wilson was CE of $A30b Australian digital-property company Rea Group Ltd.

Staff reporters 04 Nov 2025